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Normal growth is a process whereby the various
systems of the body increase their size, brought
about by an increase in cell number, cell size, or
both [1]. When growth is disturbed, either one or
both processes may be affected. When there is a re-
lease from growth-retarding influences, catch-up
growth may occur, and both cell number and size
may increase.
This is a review of the evidence that growth hor-
mone (GH) operates primarily to increase cell num-
ber, and insulin acts primarily to increase cell size.
While this report does not focus specifically on how
the action of these hormones may be affected in
children with kidney disease, it provides a basis on
which some hypotheses can be formulated and test-
ed. An interdependence between GH and insulin
has been established for some time. Mirsky [21
showed that pancreatic islets of Langerhans were
essential to support the nitrogen-retaining effect of
GH, and a series of studies subsequently demon-
strated that the action of GH to stimulate growth
required the presence of insulin [3—8].
The development of methods [9] for estimating
muscle or organ mass, cell number, and cell size
provides us with a tool for describing which of these
processes are most affected in the various disorders
of growth [10, 11]. The major effect of GH to in-
crease cell numbers is demonstrated in studies of
GH deficiency and the effect of this deficiency on
growth. Insulin is required for GH to have a maxi-
mum effect. The major effect of insulin, to increase
cell size, can be examined in patients or experimen-
tal rats with insulin deficiency.
Muscle mass, cell number, and cell size, and their
relation to net gain in protein
Much of the work cited in this report, especially
our own work, deals with muscle. Because muscle
mass cannot be measured directly in the human, an
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indirect method must be used. We have used the
daily excretion rate of creatinine as a suitable mea-
sure of muscle mass, and we have used the equation
that 1 kg of muscle generates production and excre-
tion of 50 mg/day of creatinine [9]. Muscle mass al-
so may be estimated from the difference between
total body water and extracellular fluid volume [111.
Muscle mass can be measured by several methods
in the rodent [9] (see also Holliday and Chantler,
this issue).
Cell number is estimated from the quantity of
deoxyribonucleic acid (DNA) in a sample of muscle
or other organ, adjusted to total muscle mass [9]. At
least 70% of muscle DNA is due to nuclei within the
myofibers. Although skeletal muscle cells are not
anatomically defined by cell membranes, the num-
ber of nuclei (6.2 of DNA/nucleus) define a cell
unit. Relative cell size is determined by the pro-
tein:DNA ratio in a muscle sample. Adipose tissue,
brain, liver, and kidney can be analyzed with the
same principle. Although liver has polyploid rather
than diploid cells, polyploid cells have a commensu-
rate increase in cytoplasm relative to DNA, and,
hence, a cell unit can be defined.
Net retention of nitrogen can be calculated from
either nitrogen balance studies of the organism or
from arteriovenus difference and blood flow mea-
surements of isolated organs. It also can be esti-
mated from the difference between steady-state
protein synthesis and degradation [12]. Com-
parative rates of protein synthesis or nitrogen bal-
ance may be inferred from the rates of incorpora-
tion of radioactively labeled amino acids with tissue
proteins, although this method, like the others, has
sources of error [13]. The methods used in this re-
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view will identify changes in cell number and cell
size in response to change in hormonal status.
Growth patterns with GH deficiency and responses to
replacement therapy
Hypopituitary states. Male hypopituitary dwarfs
respond to GH with a greater increase in muscle
growth than in skeletal growth [14—16] as also do
hypophysectomized rats [17—19]. The principal fac-
tor to account for the accelerated growth of muscle
is an increase in cell number. Liver and kidney are
similarly affected [191. Insulin given to hypophy-
sectomized rats has no effect on muscle cell number
(it has some effect on liver) [17]; it leads to in-
creased cell size in both [20, 211. The specificity of
the findings in hypopituitary states is not clear.
Both pituitary-deficient children and experimental
hypophysectomy create other hormone defi-
ciencies, so that the findings in untreated states or
the effects of replacement therapy may be influ-
enced by these other deficiencies.
Growth following pituitary removal. Children
may experience rapid growth [221 despite low levels
of GH in plasma following hypophysectomy for re-
moval of a craniopharyngioma. These patients have
normal or high insulin responses to either glucose or
tolbutamide administration; their somatomedin lev-
els are normal. It is speculated that high levels of
insulin may stimulate release of somatomedin, as
occurs in rat liver perfusion studies, and this ac-
counts for the growth spurt following hypophysec-
tomy [231. Rats, immediately following hypophy-
sectomy, grow for a period of 2 to 3 weeks, during
which time muscle mass may increase by 60 to 90%
[241. This growth is characterized principally by in-
crease in cell size or protein:DNA ratio. The admin-
istration of Gil with or without long-acting epineph-
rifle (which suppresses insulin release) leads to cell
replication and growth. Cell size is reduced to nor-
mal. Giving insulin to rats after hypophysectomy
has no effect.
Growth patterns in mice with congenital GH defi-
ciency and the effect of replacement therapy. Eich-
er and Beamer [25, 26] recently described mice with
an autosomal recessive defect which appears to be a
selected deficiency of OH and prolactin. The homo-
zygous (lit/lit) state resembles type I OH deficiency
in humans. Lit/lit female mice are small but propor-
tional; they do not have normal growth spurts in the
neonatal and pubertal periods. The females, how-
ever, do grow with repetitive pregnancies and can
achieve normal weights after multiple pregnancies.
Pituitary homogenates from lit/lit mice are deficient
in both GH and prolactin. The administration of OH
or implantation of a normal pituitary to these mice
leads to normal growth.
When we examined muscle in lit/lit mice, using
heterozygous mice (lit/+) for controls, muscle mass
and muscle cell number were greatly decreased
(Table I). Total RNA in muscle also was decreased.
In contrast, muscle cell size was increased above
controls. These findings are similar to those ob-
served in hypophysectomized rats and in children
with GH deficiency (see above).
The effects of giving GH to lit/lit mice are weight
gain, growth in muscle mass, and an increase in cell
number (DNA) and total muscle RNA; cell size de-
clines. GH also causes an increase in thymidine up-
take in muscle DNA. Insulin injections, in the doses
used, cause some increase in body weight, no gain
in muscle, DNA, or RNA, and no increase in cell
size. These findings provide additional evidence
that OH mediates the influence upon growth by
causing cell replication more than by causing an in-
crease in cell size. When OH is deficient, insulin
may cause an increase in muscle due to an increase
in cell size. Insulin in the absence of OH causes no
increase in cell number.
Growth with insulin excess and deficiency and the effect
of replacement therapy in insulin-deficient states
Infants born of diabetic mothers. Infants born of
diabetic mothers may have macrosomia and large
muscle and adipose tissue mass. These and certain
other characteristics of affected infants are attrib-
uted to hyperinsulinism [27]. We have studied the
newborn of the primate macaca mulatta where the
mother was made diabetic by injection of strepto-
zotocin (SZ) at 100 days into the 165-day gestation
period. The mothers developed mild diabetes. The
newborns were plethoric, had macrosomia [10], and
their pituitary, heart, carcass (muscle and skeletal
mass), spleen, and adrenals were enlarged. Cell size
(protein:DNA ratio) in skeletal muscle was ele-
vated. Surprisingly, cerebral protein:DNA ratio al-
so was increased; cerebral zinc (Zn) and Zn:DNA
ratio (both indices of cell size) also were increased.
Brain water was reduced. Changes in brain intracell-
ular amino acids suggested a higher transport rate
of amino acids into brain as well as increased pro-
tein synthesis [28]. Although there are other endo-
crine effects associated with this state in the new-
borns, the findings are characteristic of hyperin-
sulinemic states.
Effects of SZ-induced insulin deficiency on cell
growth and the effects of replacement therapy. We
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Table 1. Female homozygous (lit/lit) mice muscle composition at 23 and 46 days vs. heterozygous (lit/+) controlsa
Body wt
g
Muscle mass
g
Total DNA
mg
Total RNA
mg
Protein : DNA
mg/mg
23 days
lit/+
Mean 8.38 2.06 2.11 2.70 198.6
SD 0.78 0.36 0.43 1.06 17.0
N 5.0 5.0 5.0 5.0 5.0
lit/lit
Mean 6.32k 158b 1.68 3.27 188.0
SD 1.01 0.27 0.21 1.26 30.3
N 5.0 5.0 5.0 5.0 5.0
46 days
lit/+
Mean 14.72 3.96 3.01 8.67 278.3
SD 1.12 0.36 0.22 0.93 14.2
N 6.0 6.0 6.0 6.0 6.0
lit/lit
Mean 8.24c 2.02 1.76 3.83 252.7
SD 0.97 0.24 0.28 1.01 27.1
N 7.0 7.0 7.0 7.0 7.0
alt is to be noted that there is significantly less DNA and RNA within muscle mass of the mice with isolated growth hormone
deficiency (lit/lit) when comparison is made with the control mice of the same age. There is no increase in the DNA within the muscle
mass from 23 to 46 days in the lit/lit mice. It can also be noted that the protein : DNA ratio is excessively high if comparison is made on
the basis of body size or muscle mass (size mates).
5P < 0.05.
CP < 0.001.
examined the effects of insulin deficiency of two dif-
ferent degrees in rats given either 50 or 70 mg/kg of
SZ at 40 days of age. The rats receiving the smaller
dose continued to gain weight at normal rates after a
brief interruption; those receiving the higher dose
failed to gain for a week, then gained slowly. Rats
treated in this manner and given insulin from the
57th to the 70th days or from the 17th to 30th day
following SZ injection also were studied. The rela-
tive effect of these procedures upon muscle mass,
cell number, cell size and RNA content were mea-
sured (Table 2). Rats that received the low dose of
SZ had no decrease in muscle mass but did have an
increase in cell number (DNA) and a decrease in
cell size (protein:DNA ratio); total RNA, was de-
creased, Insulin therapy reversed these effects.
Rats that received the larger SZ dose had a much
smaller muscle mass (50% of control) and a de-
crease in both cell number and size. Insulin therapy
to this group partially restored these effects.
The effects observed with low-dose SZ are con-
sistent with a degree of insulin insufficiency; these
effects were reversed by giving insulin. The effects
seen with higher doses of SZ were those character-
istic of a more profound disturbance in growth. SZ
given to rats has been associated with a decrease in
somatomedin A, giving insulin but not GH elevates
somatomedin levels [29]. Insulin levels measured in
these rats reflect the degree of insulin deficiency
produced by SZ; insulin replacement restores in-
sulin values to normal in the low-dose rats, and to-
ward normal in the high-dose rats. Glucagon was
reduced to a lesser degree in SZ-treated rats; the
insulin:glucagon ratio was, therefore, markedly re-
duced. Giving insulin to SZ-treated rats further sup-
pressed glucagon levels and restored the in-
sulin:glucagon ratios to normal.
Insulin effects on protein synthesis in muscle using in
vitro studies
A direct effect of insulin is to increase amino acid
transport into cells to increase protein synthesis and
to decrease protein degradation in muscle [30]. In
vitro incubation studies of diaphragm and perfusion
studies of liver, heart, and hind limb have each been
used to isolate the modes of action of insulin. This
effect of insulin upon muscle protein synthesis is
not dependent on its effect on glucose or amino
acid uptake, and insulin does not change adeno-
sine triphosphate in cells in stimulating protein syn-
thesis. Its effect is linked to ribosome-associated
reactions [31].
While in vitro studies often fail to reproduce the
conditions that are present in in vivo studies, they
do provide a means for ferreting out the various bio-
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Table 2. Estimates of cell size and total nuclear number in muscle mass in rats following streptozotocin (SZ) at 40th day with and without
insulin treatment from 57th to 70th days, compared with controlsa
Treatment
group
Muscle mass
g Protein DNA
Muscle nuclei
x l0 Total RNAmg
Controls
Mean 81.34 340.2 8.32 162.15
SD 5.32 17.7 0.42 8.74
50mg SZ/kg body wt
Saline
Mean 82.48 290.9k 974C 12463d
SD 11.25 21.3 1.27 16.73
Insulin
Mean 76.96 311.6e 8.44 164,60
so 8.19 16.0 1.02 19.81
70mg SZ/kg body wt
Saline
Mean 41.89 286.6C 550d 82,36d
so 5.39 62.1 1.02 18.97
Insulin
Mean 66.82 330.9 6.91c 151.30
SD 1.91 31.0 0.96 37.17
N = 6 rats for all groups.
bp < .005 when compared with age controls.
p < .05 when compared with age controls.
'p < .001 when compared with age controls.
Cytoplasmic index showed significant reduction (nonchloride space of muscle/DNA).
chemical processes that insulin effects. A review of
these may suggest an approach to determining
whether insulin resistance plays a part in the poor
nutritional state often seen in uremia. This ap-
proach also provides a means for studying specific
hormonal effects, undisturbed by secondary hor-
monal changes that occur in vivo. On the other
hand, in vivo studies provide a better method for
examining the overall effects of hormonal balance in
relation to nutritional state and growth. For that
reason, we have used in vivo studies to examine the
effect of GH and insulin upon growth.
Other hormonal effects that may be secondary to the
effects of GH or insulin
Somatomedin. A review is given elsewhere in
this symposium (Lewy and Van Wyk, this issue) of
the assay methods and present understanding about
the family of peptides, somatomedins, and how
they may affect growth. GH is concerned with re-
lease of somatomedins A and B. Somatomedin B
may be the factor that initiates the GH stimulus to
cell multiplication. Somatomedin A closely resem-
bles insulin and may account for much of the non-
suppressible insulin-like activity (NSILA) in plasma
[32—331. Some of the control for release of these and
related hormones is located in the brain [341. Obesi-
ty induced by ventromedial hypothalamic lesions
may mediate its effect through changes in GH and
insulin imbalances [351, an effect that may be trans-
mitted by parasympathetic stimulation or by release
of a very active peptide [36].
Sex hormones. Sex differences in muscle and adi-
pose tissue growth rates occur at puberty. Boys ex-
perience a doubling in muscle mass, much of which
is related to an increase in cell numbers, and less to
an increase in protein:DNA ratio. Girls experience
a smaller growth rate in muscle due to a lesser in-
crease in cell numbers. We have suggested that this
difference is related to the effect of testosterone to
augment GH release in males and stimulate cell
numbers; estrogen, in contrast, inhibits the periph-
eral action of GH [211.
Thyroid hormone. Thyroid hormone also is an
important regulator of prenatal growth, but is less
important as a regulator of postnatal growth. In-
fants with congenital hypothyroid states have a low
protein:DNA ratio, whereas preadolescent children
who develop hypothyroid states tend to have an ele-
vated protein:DNA ratio in muscle. Hypothy-
roidism induced in rats is associated with an in-
crease in insulin levels and a decrease in GFI levels
[37, 38]. In rats made hyperthyroid, insulin secre-
tion is low [391.
Thyroid hormone is also recognized as a regula-
tor of the basal metabolic rate, which is mediated
through a change in sodium-potassium-dependent
ATPase activity (Na-K-ATPase) and sodium trans-
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port [38]. Na-K-ATPase activity has been corre-
lated with proten-synthesizing activity of lympho-
blasts [40]. Na-K-ATPase activity of isolated muscle
membrane is not influenced by addition of insulin,
but incubation of muscle with insulin prior to mem-
brane isolation causes an increase in Na-K-ATPase
activity. Inhibition of ATPase activity has been cor-
related with severe uremia [411. At present, these
"loose threads" can only suggest ways that uremia
may adversely affect body protein:nitrogen balance
through effects on insulin activity related to protein
synthesis and degradation.
Summary
The growth-regulating property of GH operates
mostly by its capacity for stimulating cell replica-
tion. Where there is a deficiency of GH (isolated
deficiency, pituitary deficiency, or hypothyroidism)
or when tissue response to GH is reduced (calorie
deficiency or estrogen excess), the effect is a dimi-
nution in cell number. In some of these instances,
an overresponse to insulin leads to an increase in
cell size (a higher protein:DNA ratio).
Insulin, in contrast, exercises its growth-promot-
ing effect by its ability to stimulate protein synthesis
and depress protein degradation; its effect is to
stimulate growth in cell size. Growth in cell size is
retarded where insulin deficiency (diabetes, protein
calorie malnutrition) or tissue resistance exists
(obesity). Imbalance in either hormone not only in-
terferes directly with growth of cells but also trig-
gers other hormonal imbalances, e.g., somatome-
din. Growth retardation in uremia has some of its
base in undernutrition, which can be mediated
through changes in hormonal balance. Uremia may
directly effect tissue response to hormone as in the
case of insulin. Future investigations of growth re-
tardation in kidney disease may find hormone im-
balance as a potential cause for growth inhibition.
It can be pointed out further that children with a
diminished nephron population are in a position
where each nephron is acting to a maximal extent to
clear waste products of metabolism. With further
growth and an increase in the number and size of
cells, the load on the kidney will increase. Hence, in
some instances it may not be wise to promote so-
matic growth. The subject is worthy of research.
Acknowledgments
This work was supported by a grant from the Na-
tional Health and Medical Research Council of Aus-
tralia.
Reprint requests to Professor D. B. Cheek, Royal Children's
Hospital Research Foundation, Fletnington Road, Parkvil/e,
Victoria, 3052, Australia.
References
I. ENESCO M, LEBLON c CP: Increase in cell number as a factor
in the growth of the organs and tissues of the young male rat.JEmbryol Exp Morph 10:530—563, 1962
2. MIRSKY IA: Influence of anterior pituitary gland on protein
metabolism. Endocrinology 25:52—56, 1939
3. SALTER J. BEST CH: Insulin as a growth hormone. Br MedJ
2:353—356, 1953
4. WAGNER EM, Scow RO: Effect of insulin on growth in
force-fed hypophysectomised rats. Endocrinology 61:419—
425, 1957
5. MILMAN AE, DEM00R P. LUKENS FDW: Relation of purl-
fled pituitary growth hormone and insulin in regulation of
nitrogen balance. Am J Physiol 166:354—363, 1951
6. Scow RO: Effect of growth hormone on growth in hypophy-
sectomised-pancreatectomised rats. Endocrinology 61:582—
586, 1957
7. Scow RO, CHERNICK SS: Hormone control of protein and
fat metabolism in the pancreatectomised rats. Recent Prog
Horm Res 16:497—504, 1960
8. GAEBLER OH, Liu CH, ZycI-ILEw5KI A: Effects of small
daily doses of growth hormone on nitrogen output in normal
and depancreatised dogs. Am J Physiol 18:357—360, 1956
9. CHEEK DB, HOLT AB, HILL DE, TALBERT JL: Skeletal
muscle, cell mass and growth: the concept of the deoxyri-
bonucleic acid unit. Pediatr Res 5:312—328, 1971
10. HOLT AB, HILL DE, CHEEK DB: Morphological and bio-
chemical correlates in brain, in Fetal and Postnatal Cellular
Growth: Hormones and Nutrition, edited by CHEEK DB.
New York, J. Wiley & Sons, 1975, pp. 45—54
11. CHEEK DB: Implications and conclusions, inFetal and Post-
natal Cellular Growth: Hormones and Nutrition, edited by
CHEEK DB, New York, J. Wiley & Sons, 1975, pp. 475-498
12. WATERLOW JC, CRAVIOTOJ, STEFHEN JML: Protein malnu-
trition in man. Adv Protein Chem 15:131—238,1960
13. GOLDBERG AL, DIA iF: Intracellular protein degradation in
mammalian and bacterial cells. Am Rev Bio Chem 43:835—
869, 1974
14. CHEEK DB: The effect of growth hormone on cell multiplica-
tion and cell size, in Human Pituitary Growth Hormone.
54th Ross Conference on Pediatric Research (1964), edited
by BLIZZARD RM, Columbus, Ross Laboratories, 1966, p.
58
15. CHEEK DB, BRASEL J, ELLIOTT D, SCOTT R: Muscle cell
size and number in normal children and in dwarfs (pituitary,
cretins, and primordial) before and after treatment. Johns
Hopkins MedJ 119:46—62, 1966
16. CHEEK DB: Cellular growth, hormones, nutrition and time
(Borden Award Address). Pediatrics 41:30—46, 1968
17. CHEEK DB, GRAYSTONE JE: The action of insulin, growth
hormone, and epinephrine on cell growth in liver, muscle
and brain of the hypophysectomised rat. Pediatr Res 3:77—
88, 1969
18. BEACH RK, KOSTYO JL: Effect of growth hormone on the
DNA content of muscles of young hypophysectomised rats.
Endocrinology 82:882—884, 1968
19. GOLD5PINK DG, GOLDBERG AL: Influence of pituitary
growth hormone on DNA synthesis in rat tissues. Am J
Physiol 228:302—309, 1975
322 Cheek and Graystone
20. CHEEK DB, HILL DE: Muscle and liver cell growth: Role of
hormones and nutritional factors. Fed Proc 29:1503—1509,
1970
21. CHEEK DB, BRASEL J, GRAYSTONE JE: Muscle cell growth
in rodents: Sex difference and the role of hormones, in Hu-
man Growth, Body Composition, Cell Growth, Energy and
Intelligence, edited by CHEEK DB, Philadelphia, Lea &
Febiger, 1968, pp. 306—325
22. C0sTIN 0, KOGUT MD, PHILLIPS LS, DAUGHADAY WH:
Craniopharyngioma: The role of insulin in promoting post-
operative growth. J Clin Endocr 42:370—379, 1976
23. DAUGHADAY WH, PHILLIPS LS, MUELLER MC: The effects
of insulin and growth hormone on the release of somato-
medin by the isolated rat liver. Endocrinology 98:1214—1219,
1976
24. CHEEK DB, WYLLIE RG: Postnatal cellular growth: Hor-
monal considerations, in Fetal and Postnatal Cellular
Growth: Hormones and Nutrition, edited by CHEEK DB,
New York, J. Wiley & Sons, 1975, pp. 415—435
25. EICHER EM, BEAMER WG: Inherited ateliotic dwarfism in
mice.JHeredity 67:87—91, 1976
26. BEAMER WG, EICHER EM: Stimulation of growth in the little
mouse. J Endocrinol 7 1:37—45, 1976
27. CHEEK DB, BRAYTON JB, SCOTT RE: Overnutrition, over-
growth and hormones (with special reference to the infant
born of the diabetic mother), in Nutrition and Malnutrition,
edited by ROCHE AF, FALKNER F, New York, Plenum Pub-
lishing Corp., 1974, pp. 47—72
28. BACHMAN C, NYHAN WL, KULOVICH 5, HORNBECK ME:
Amino acids in the brain during fetal growth and the effects
of prenatal hormonal and nutritional imbalance, in Fetal and
Postnatal Cellular Growth: Hormones and Nutrition, edited
by CHEEK DB, New York, J. Wiley & Sons, 1975, pp. 169—
205
29. PHILLIPS LS, YOUNG HS: Nutrition and somatomedin: 11.
Serum somatomedin activity and carilage growth activity in
streptozatocin-diabetic rats. Diabetes 25:516—517, 1976
30. JEFFERSON LS, RANNELS DE, MUNGER BL, MORGAN HE:
Insulin in the regulation of protein turnover in heart and
skeletal muscle. Fed Proc 33:1098—1104, 1974
31. WOOL IG: Insulin and the regulation of protein synthesis in
muscle. Proc Nutr Soc 31:185—191, 1972
32. RINDERKNECHT E, HUMBEL RD: Amino-terminal sequences
of two polypeptides from human serum with non-
suppressible insulin-like and cell growth-promoting activi-
ties: Evidence for structural homology with insulin f3 chain.
Proc NatI Acad Sci 73:4379—82, 1976
33. KAHN CR, MEGYESI K, ROTH J: Nonsuppressible insulin-
like activity of human serum. J Clin Invest 57:526—529, 1976
34. Woos SC, PORTE D: Neural control of the endocrine pan-
creas. Physiol Rev 54:596—619, 1974
35. MARTIN JM, KONIJNEND1JK W, BOUMAN PD: Insulin and
growth hormone secretion in rats with ventral medial hypo-
thalamic lesions maintained on restricted food intake. Dia-
betes 25:203—208, 1974
36. LOCKHART-EWART RB, MOK C, MARTIN JM: Neuroendo-
crine control of insulin secretion. Diabetes 25:96—100, 1976
37. LENZEN S, JoosT HG, HASSELBLATT A: Thyroid function
and insulin secretion from the perfused pancreas in the rat.
Endocrinology 99:125-129, 1976
38. EDELMAN 15: Thyroid hormone action. N Engi J Med
290:1303—1308, 1974
39. BRODAL BP, JEBENS H, 0 V. IVERSON 0-i: Effect of in-
sulin on (Na, K)-activated adenosine triphosphate activity
in rat muscle sarcolemma. Nature 249:41—43, 1974
40. SHANK BB, SMITH NE: Regulation of cellular growth by so-
dium pump activity. J Cell Physiol 87:377-388, 1976
41. MEDZIHRUDSKY G, SELLENGER OZ, NANDHASRI PS, SAN-
TIAGO JC: Adenosine triphosphatase activity in glial cells
and in neuronal perikarya of edematous rat brain. Brain Res
67:133—139, 1974
